Alnylam Pharmaceuticals Inc
LSE:0HD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
I
|
Illumina Inc
F:ILU
|
US |
|
A
|
American International Group Inc
BMV:AIG
|
US |
|
M
|
Mitsubishi Chemical Group Corp
XMUN:M3C
|
JP |
|
V
|
Vericel Corp
F:ATQP
|
US |
|
C
|
Cadence Design Systems Inc
XBER:CDS
|
US |
|
E
|
Eagle Materials Inc
XBER:E5M
|
US |
|
B
|
BCE Inc
XMUN:BCE1
|
CA |
|
C
|
Chow Tai Fook Jewellery Group Ltd
XBER:1CT
|
HK |
|
B
|
Brookdale Senior Living Inc
F:B7S
|
US |
|
Ranpak Holdings Corp
NYSE:PACK
|
US |
|
Fortescue Metals Group Ltd
F:FVJA
|
AU |
|
G
|
Gildan Activewear Inc
XBER:VGA
|
CA |
|
Eenergy Group PLC
F:A1Z1
|
UK |
|
K
|
Kinder Morgan Inc
F:2KD
|
US |
|
C
|
Cushman & Wakefield PLC
F:2IY
|
UK |
|
Invitation Homes Inc
F:4IV
|
US |
|
C
|
Compass Inc
NYSE:COMP
|
US |
|
L
|
LH Shopping Centers Leasehold Real Estate Investment Trust
SET:LHSC
|
TH |
|
E
|
Energy Recovery Inc
F:5E2
|
US |
|
M
|
Mitsubishi Chemical Group Corp
DUS:M3C
|
JP |
|
C
|
Callaway Golf Co
XBER:CLY
|
US |
|
A
|
Axon Enterprise Inc
F:TCS
|
US |
|
Brookfield Corp
F:K7X
|
CA |
Wall St Price Targets
0HD2 Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0HD2 is 371.375 USD with a low forecast of 228.434 USD and a high forecast of 584.409 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0HD2's stock price target?
Price Target
371.375
USD
According to Wall Street analysts, the average 1-year price target for 0HD2 is 371.375 USD with a low forecast of 228.434 USD and a high forecast of 584.409 USD.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
19%
The compound annual growth rate for Gross Profit over the next 8 years is 19%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
37%
The compound annual growth rate for Operating Income over the next 8 years is 37%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
91%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 91%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
40%
The compound annual growth rate for Net Income over the next 8 years is 40%.
